Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment
Open Access
- 23 July 2002
- Vol. 95 (3) , 605-612
- https://doi.org/10.1002/cncr.10687
Abstract
BACKGROUND Brain metastases (BM) are frequent sites of initial failure in patients with locally advanced nonsmall cell lung cancer (LAD-NSCLC) undergoing multimodality treatments (MMT). New treatment and follow-up strategies are needed to reduce the risk of BM and to diagnose them early enough for effective treatment. METHODS The incidence rate of BM as the first site of recurrence in 112 patients with LAD-NSCLC treated with the same MMT protocol was calculated. The influence of patient, disease, and treatment-related factors on the incidence of BM and on the time-to-brain recurrence (TBR) was analyzed. RESULTS BM as the first site of failure was observed in 25 cases (22% of the study population and 29% of all recurrences). In 18 of those cases, the brain was the exclusive site of recurrence. Median TBR was 9 months. The 2-year actuarial incidence of BM was 29%. Central nervous system (CNS) recurrence was more common in patients younger than 60 years (P = 0.006) and in whom bulky (≥ 2 cm) mediastinal lymph nodes were present (P = 0.02). TBR was influenced by age (P = 0.004) and by bulky lymph node disease (P = 0.003). Multivariate analysis confirmed the prognostic role of age, whereas the presence of clinical bulky mediastinal lymph nodes was of borderline significance. CONCLUSIONS Our study confirmed a high rate of BM in patients with LAD-NSCLC submitted to MMT. Most of these CNS recurrences were isolated and occurred within 2 years of initial diagnosis. Age younger than 60 years was associated with an increased risk of BM and reduced TBR, whereas the presence of clinical bulky mediastinal lymph nodes was of borderline significance. Although our data require further validation in future studies, our results suggest that additional trials on prophylactic cranial irradiation and on intensive radiologic follow-up should focus on these high-risk populations. Cancer 2002;95:605–12. © 2002 American Cancer Society. DOI 10.1002/cncr.10687Keywords
This publication has 40 references indexed in Scilit:
- Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapyCancer, 2001
- Topotecan - A New Treatment Option in the Therapy of Brain Metastases of Lung CancerPublished by S. Karger AG ,1999
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsPublished by Elsevier ,1997
- Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2): Analysis of Cancer and Leukemia Group B Protocol 8935Cancer, 1996
- Brain metastasis in resected lung cancer: Value of intensive follow-up with computed tomographyThe Annals of Thoracic Surgery, 1996
- Results of cancer and leukemia group B protocol 8935The Journal of Thoracic and Cardiovascular Surgery, 1995
- Surgery following neoadjuvant MPV chemotherapy (mitomycin, cisplatin, vinblastine) in locally advanced (IIIa and IIIb) non-small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 1994
- Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patientsThe Annals of Thoracic Surgery, 1993
- Survival after resection of stage II non-small cell lung cancerThe Annals of Thoracic Surgery, 1992
- Intracranial Recurrence of Carcinoma after Complete Surgical Resection of Stage I, II, and III Non-Small-Cell Lung CancerNew England Journal of Medicine, 1988